Skip to main content
. 2021 Feb 23;39(12):1317–1328. doi: 10.1200/JCO.20.01366

FIG 2.

FIG 2.

PFS, EFS, and OS in the intent-to-treat population: (A) progression-free survival by Independent Radiology Adjudication Committee (IRAC) assessment; (B) event-free survival by IRAC assessment; (C) OS. EFS, event-free survival; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R2-CHOP, lenalidomide plus R-CHOP.